An ex vivo method of diagnosing Alzheimer's disease comprising the steps of analysing a cerebrospinal fluid (CSF) sample taken from a patient with regard to a concentration of at least one amyloid precursor protein (APP) product selected from the group consisting of soluble forms of amyloid precursor protein α and β (sAPPα and sAPPβ); comparing the concentration of the at least one APP product with a threshold-value for the concentration of the respective one APP product; and indicating a probability that the patient has or is prone to Alzheimer's disease, if the concentration of the at least one APP product exceeds the threshold-value for the concentration of the respective one APP product.
展开▼